DEZHAN HEALTHCARE(SZ:000813)2021-08-27 16:00Financial Performance - The company's operating revenue for the first half of 2021 was ¥391,820,103.30, a decrease of 45.17% compared to ¥714,601,279.87 in the same period last year[29]. - The net profit attributable to shareholders for the first half of 2021 was ¥102,591,331.02, down 43.77% from ¥182,437,104.68 in the previous year[29]. - The net cash flow from operating activities was ¥156,926,755.49, representing a significant decline of 79.18% compared to ¥753,682,581.12 in the same period last year[29]. - Basic earnings per share for the first half of 2021 were ¥0.0458, a decrease of 44.35% from ¥0.0823 in the previous year[29]. - Total assets at the end of the reporting period were ¥6,065,391,673.74, down 5.22% from ¥6,399,443,473.17 at the end of the previous year[29]. - The net assets attributable to shareholders decreased by 6.21%, from ¥5,897,405,033.41 to ¥5,531,147,661.76[29]. - The weighted average return on net assets was 1.75%, down 1.45% from 3.20% in the previous year[29]. - The net profit after deducting non-recurring gains and losses was ¥91,322,843.55, a decrease of 43.68% from ¥162,161,936.88 in the same period last year[29]. - The company achieved operating revenue of 391.82 million yuan, a decrease of 45.17% compared to the same period last year[47]. - The net profit attributable to shareholders was 102.59 million yuan, down 43.77% year-on-year[47]. - The total assets amounted to 6.07 billion yuan, a decline of 7.72% from the previous year[47]. - The cost of goods sold was ¥123,323,997.59, down 31.17% from ¥179,176,289.08, primarily due to reduced sales volume[55]. - Research and development expenses increased by 55.71% to ¥33,910,813.92 from ¥21,778,542.84, reflecting increased investment in R&D projects[55]. - The gross profit margin for the pharmaceutical sector was 68.64%, down 6.92% from the previous year[59]. - The sales revenue from pharmaceutical products was ¥377,605,541.89, representing 96.37% of total revenue, with a year-on-year decrease of 45.91%[58]. Business Strategy and Development - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company has highlighted potential risks and countermeasures in its future development strategy[6]. - The core drug "Alet" (Atorvastatin Calcium Tablets) is positioned as a market leader, being the first in China to pass the consistency evaluation for this product[39]. - The company has obtained registration certificates for two specifications of Amlodipine Atorvastatin Calcium Tablets and is actively promoting their production and sales[39]. - The company is diversifying into new business areas, including biopolypeptides, food and beverages, and cosmetics, while also being the exclusive agent for Taiwan's Guoguang flu vaccine in mainland China[39]. - The company’s marketing strategy for its pharmaceutical business includes a distributor and promoter model, focusing on "sales-driven production"[40]. - The company aims to enhance brand recognition and product awareness through various promotional activities, including seasonal promotions and participation in industry exhibitions[41]. - The company is focusing on expanding its OTC market presence and enhancing product promotion in retail pharmacies[41]. - The company is actively expanding its product pipeline, including new flavors and packaging for the "Xiao Lan" beverage series expected to launch in Q3[48]. - The company is collaborating with a subsidiary on a DNA therapeutic drug project, which has shown positive results in a Phase III clinical trial[161]. - The company is actively pursuing market expansion and new product development strategies[164]. Risks and Challenges - The company faces market and policy risks due to ongoing pharmaceutical policy reforms and increasing regulatory scrutiny, which may impact operations[78]. - The company plans to enhance R&D investment and innovate drug development to mitigate risks associated with drug procurement policies and market competition[78]. - The company faces increased risks in quality control due to stricter regulations on drug development and marketing, necessitating robust internal controls to ensure drug safety[81]. - Rising production costs are anticipated due to increases in raw material prices, logistics costs, and labor, prompting the company to implement a qualified supplier management system and innovate production technologies to control costs[81]. - New business ventures, particularly in food and beverage and peptide cosmetics, face risks from macroeconomic fluctuations, potential policy changes, and intensified market competition[81]. - The company plans to adhere strictly to national laws and regulations regarding new business collaborations, particularly in the industrial hemp sector, to mitigate associated risks[82]. Environmental Compliance - Environmental compliance is maintained, with no exceedances reported in pollutant emissions across various categories[96]. - The company has implemented a wastewater treatment facility that is operating normally, ensuring compliance with environmental standards[106]. - The company has upgraded its boiler to low-nitrogen specifications, reducing pollutant emissions[106]. - The wastewater treatment plant's effluent quality, including pH, suspended solids, BOD, COD, total nitrogen, ammonia nitrogen, and total phosphorus, meets environmental discharge standards[106]. - The company has set up a hazardous waste storage facility, ensuring proper classification and storage of hazardous materials[106]. - The company has conducted VOC modification projects in its solid preparation workshop, ensuring compliance with emission standards[106]. - The company has developed an emergency response plan for environmental incidents, which includes regular drills to ensure preparedness[112]. - The company has established a comprehensive self-monitoring plan for emissions, ensuring regular data recording and compliance with environmental standards[111]. Shareholder and Corporate Governance - The annual shareholders' meeting had a participation rate of 59.37%, where key resolutions including the profit distribution plan and adjustments to fundraising projects were approved[86]. - The company has implemented an employee stock ownership plan, with a total of 2,665,113 shares subscribed at a price of 9.93 yuan per share, amounting to 26.4646 million yuan[90]. - The first phase of the company's stock incentive plan was approved, granting a total of 21,612,228 restricted shares at a price of 1.85 yuan per share[91]. - The company has not distributed cash dividends or bonus shares for the half-year period[87]. - The company reported a total share capital of 2,241,481,800 shares, with 99.04% being unrestricted shares[170]. - The company’s financial statements for 2020 received a qualified opinion from the auditing firm, indicating potential issues[165]. - The board of directors is addressing the audit firm's qualified opinion by communicating with trust institutions to mitigate risks, with a total of 20 million yuan in principal and corresponding investment income already redeemed as of June 30, 2021[127]. - The company has no significant litigation or arbitration matters during the reporting period[129]. - There are no major related party transactions reported during the period[130]. - The company has engaged in entrusted financial management with a total amount of 70 million yuan, including 18 million yuan in bank financial products and 42 million yuan in trust financial products[144]. - The overdue amount from entrusted financial management is 738.65 thousand yuan, which has been fully provisioned for impairment[144]. - The company has no major guarantees during the reporting period[143]. - The company has not experienced any bankruptcy reorganization matters during the reporting period[128]. - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period[186]. - The company has no preferred shares in existence during the reporting period[190].